Manufacturers are being pushed beyond mAb‑era platforms into a new design model built around molecular engineering, complex ...

Thanks in part to the revolution cell therapy brought to treating blood cancers, the modality is now showing promise in some ...

AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning ...

In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and ...

Limited opportunities and burnout are just two reasons biopharma professionals stop looking for work, with some pivoting away ...

Two recruiting experts discuss the main areas where biopharma employers and candidates don’t match up, from how the hiring ...

Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other ...

Biopharmas developing CAR T therapies for autoimmune indications face major barriers to maximizing the market. Advances in ...

Vitruvias Therapeutics has “ceased operations” after voluntarily recalling a batch recall of generic thyroid tablets due to ...

The FDA granted the approval of Revolution Medicines' daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma ...

The Phase 3 readout is the first for ivonescimab beyond non-small cell lung cancer to show a significant overall survival ...

Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its ...